Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2013, Article ID 578480, 16 pages
http://dx.doi.org/10.1155/2013/578480
Review Article

Blocking Neurogenic Inflammation for the Treatment of Acute Disorders of the Central Nervous System

Adelaide Centre for Neuroscience Research, School of Medical Sciences, The University of Adelaide, North Terrace, SA 5005, Australia

Received 6 February 2013; Accepted 8 May 2013

Academic Editor: Christopher D. Buckley

Copyright © 2013 Kate Marie Lewis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Pfeifer, I. S. Tarkin, B. Rocos, and H. C. Pape, “Patterns of mortality and causes of death in polytrauma patients-Has anything changed?” Injury, vol. 40, no. 9, pp. 907–911, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. E. Mautes, M. R. Weinzierl, F. Donovan, and L. J. Noble, “Vascular events after spinal cord injury: contribution to secondary pathogenesis,” Physical Therapy, vol. 80, no. 7, pp. 673–687, 2000. View at Google Scholar · View at Scopus
  3. V. Bartanusz, D. Jezova, B. Alajajian et al., “The blood-spinal cord barrier: morphology and clinical implications,” Annals of Neurology, vol. 70, no. 2, pp. 194–206, 2011. View at Google Scholar
  4. G. L. Suidan, J. R. Mcdole, Y. Chen, I. Pirko, and A. J. Johnson, “Induction of blood brain barrier tight junction protein alterations by CD8 T cells,” PLoS ONE, vol. 3, no. 8, Article ID e3037, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Silwedel and C. Förster, “Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli,” Journal of Neuroimmunology, vol. 179, no. 1-2, pp. 37–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Petty and E. H. Lo, “Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation,” Progress in Neurobiology, vol. 68, no. 5, pp. 311–323, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Persidsky, S. H. Ramirez, J. Haorah, and G. D. Kanmogne, “Blood-brain barrier: structural components and function under physiologic and pathologic conditions,” Journal of Neuroimmune Pharmacology, vol. 1, no. 3, pp. 223–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Joó, “Endothelial cells of the brain and other organ systems: some similarities and differences,” Progress in Neurobiology, vol. 48, no. 3, pp. 255–273, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Baumann, E. Preston, J. Slinn, and D. Stanimirovic, “Post-ischemic hypothermia attenuates loss of the vascular basement membrane proteins, agrin and SPARC, and the blood-brain barrier disruption after global cerebral ischemia,” Brain Research, vol. 1269, pp. 185–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Bundgaard and N. J. Abbott, “All vertebrates started out with a glial blood-brain barrier 4-500 million years ago,” GLIA, vol. 56, no. 7, pp. 699–708, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Kim, J. A. Park, S. W. Lee et al., “Blood-neural barrier: intercellular communication at glio-vascular interface,” Journal of Biochemistry and Molecular Biology, vol. 39, no. 4, pp. 339–345, 2006. View at Google Scholar · View at Scopus
  12. C. Escartin and G. Bonvento, “Targeted activation of astrocytes: a potential neuroprotective strategy,” Molecular Neurobiology, vol. 38, no. 3, pp. 231–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Fisher, “Pericyte signaling in the neurovascular unit,” Stroke, vol. 40, no. 3, supplement, pp. S13–S15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Joo, “The blood-brain barrier in vitro: the second decade,” Neurochemistry International, vol. 23, no. 6, pp. 499–521, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Rhine, S. L. Wade, K. L. Makoroff et al., “Clinical predictors of outcome following inflicted traumatic brain injury in children,” Journal of Trauma and Acute Care Surgery, vol. 73, no. 9, supplement 3, pp. S248–S253, 2012. View at Google Scholar
  16. J. R. Wilson, R. G. Grossman, R. F. Frankowski et al., “A clinical prediction model for long-term functional outcome after traumatic spinal cord injury based on acute clinical and imaging factors,” Journal of Neurotrauma, vol. 29, no. 13, pp. 2263–2271, 2012. View at Google Scholar
  17. I. Klatzo, “Pathophysiological aspects of brain edema,” Acta Neuropathologica, vol. 72, no. 3, pp. 236–239, 1987. View at Google Scholar · View at Scopus
  18. C. Ayata and A. H. Ropper, “Ischaemic brain oedema,” Journal of Clinical Neuroscience, vol. 9, no. 2, pp. 113–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Lazovic, A. Basu, H. W. Lin et al., “Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection,” Stroke, vol. 36, no. 10, pp. 2226–2231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kuroiwa, M. Ueki, Q. Chen, H. Suemasu, I. Taniguchi, and R. Okeda, “Biomechanical characteristics of brain edema: the difference between vasogenic-type and cytotoxic-type edema,” Acta Neurochirurgica, Supplement, vol. 60, pp. 158–161, 1994. View at Google Scholar · View at Scopus
  21. T. Kuroiwa, R. Cahn, and M. Juhler, “Role of extracellular proteins in the dynamics of vasogenic brain edema,” Acta Neuropathologica, vol. 66, no. 1, pp. 3–11, 1985. View at Google Scholar · View at Scopus
  22. T. Kuroiwa, P. Ting, H. Martinez, and I. Klatzo, “The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion,” Acta Neuropathologica, vol. 68, no. 2, pp. 122–129, 1985. View at Google Scholar · View at Scopus
  23. A. W. Unterberg, J. Stover, B. Kress, and K. L. Kiening, “Edema and brain trauma,” Neuroscience, vol. 129, no. 4, pp. 1021–1029, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. D. Habgood, N. Bye, K. M. Dziegielewska et al., “Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice,” European Journal of Neuroscience, vol. 25, no. 1, pp. 231–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. L. J. Noble and J. R. Wrathall, “Distribution and time course of protein extravasation in the rat spinal cord after contusive injury,” Brain Research, vol. 482, no. 1, pp. 57–66, 1989. View at Google Scholar · View at Scopus
  26. P. G. Popovich, P. J. Horner, B. B. Mullin, and B. T. Stokes, “A quantitative spatial analysis of the blood-spinal cord barrier I. Permeability changes after experimental spinal contusion injury,” Experimental Neurology, vol. 142, no. 2, pp. 258–275, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Y. Hsu, T. H. Liu, J. Xu et al., “Arachidonic acid and its metabolites in cerebral ischemia,” Annals of the New York Academy of Sciences, vol. 559, pp. 282–295, 1989. View at Google Scholar · View at Scopus
  28. M. Smith, “Monitoring intracranial pressure in traumatic brain injury,” Anesthesia and Analgesia, vol. 106, no. 1, pp. 240–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. F. Hanley, “Review of critical care and emergency approaches to stroke,” Stroke, vol. 34, no. 2, pp. 362–364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Hacke, S. Schwab, M. Horn, M. Spranger, M. De Georgia, and R. Von Kummer, “‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs,” Archives of Neurology, vol. 53, no. 4, pp. 309–315, 1996. View at Google Scholar · View at Scopus
  31. G. Gartshore, J. Patterson, and I. M. Macrae, “Influence of ischemia and reperfusion on the course of brain tissue swelling and blood-brain barrier permeability in a rodent model of transient focal cerebral ischemia,” Experimental Neurology, vol. 147, no. 2, pp. 353–360, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Torre-Healy, N. F. Marko, and R. J. Weil, “Hyperosmolar therapy for intracranial hypertension,” Neurocritical Care, vol. 17, no. 1, pp. 117–130, 2012. View at Google Scholar
  33. F. Sadaka and C. Veremakis, “Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review,” Brain Injury, vol. 26, no. 7-8, pp. 899–908, 2012. View at Google Scholar
  34. J. V. Rosenfeld, A. I. Maas, P. Bragge et al., “Early management of severe traumatic brain injury,” The Lancet, vol. 380, no. 9847, pp. 1088–1098, 2012. View at Google Scholar
  35. R. J. Hurlbert, “Strategies of medical intervention in the management of acute spinal cord injury,” Spine, vol. 31, no. 11, supplement, pp. S16–S21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. C. Furlan, V. Noonan, D. W. Cadotte, and M. G. Fehlings, “Timing of decompressive surgery of spinal cord after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies,” Journal of Neurotrauma, vol. 28, no. 8, pp. 1371–1399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Severini, G. Improta, G. Falconieri-Erspamer, S. Salvadori, and V. Erspamer, “The tachykinin peptide family,” Pharmacological Reviews, vol. 54, no. 2, pp. 285–322, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. P. H. Black, “Stress and the inflammatory response: a review of neurogenic inflammation,” Brain, Behavior, and Immunity, vol. 16, no. 6, pp. 622–653, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Harrison and P. Geppetti, “Substance P,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 6, pp. 555–576, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Saria and J. M. Lundberg, “Capsaicin pretreatment inhibits heat-induced oedema in the rat skin,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 323, no. 4, pp. 341–342, 1983. View at Google Scholar · View at Scopus
  41. M. Otsuka and K. Yoshioka, “Neurotransmitter functions of mammalian tachykinins,” Physiological Reviews, vol. 73, no. 2, pp. 229–308, 1993. View at Google Scholar · View at Scopus
  42. P. Holzer, “Neurogenic vasodilatation and plasma leakage in the skin,” General Pharmacology, vol. 30, no. 1, pp. 5–11, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. K. M. Lewis, E. Harford-Wright, R. Vink et al., “Targeting classical but not Neurogenic inflammation reduces peritumoral edema in secondary brain tumors,” Journal of Neuroimmunology, vol. 250, no. 1-2, pp. 59–65, 2012. View at Google Scholar
  44. M. B. Graeber, W. Li, and M. L. Rodriguez, “Role of microglia in CNS inflammation,” The FEBS Letters, vol. 585, no. 23, pp. 3798–3805, 2011. View at Google Scholar
  45. J. J. Donkin and R. Vink, “Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments,” Current Opinion in Neurology, vol. 23, no. 3, pp. 293–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. Caterina, M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389, no. 6653, pp. 816–824, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Tominaga, M. J. Caterina, A. B. Malmberg et al., “The cloned capsaicin receptor integrates multiple pain-producing stimuli,” Neuron, vol. 21, no. 3, pp. 531–543, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. J. D. Richardson and M. R. Vasko, “Cellular mechanisms of neurogenic inflammation,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 3, pp. 839–845, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. G. D. Nicol and M. Cui, “Enhancement by prostaglandin E2 of bradykinin activation of embryonic rat sensory neurones,” Journal of Physiology, vol. 480, no. 3, pp. 485–492, 1994. View at Google Scholar · View at Scopus
  50. R. V. Alves, M. M. Campos, A. R. S. Santos, and J. B. Calixto, “Receptor subtypes involved in tachykinin-mediated edema formation,” Peptides, vol. 20, no. 8, pp. 921–927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. M. M. Campos and J. B. Calixto, “Neurokinin mediation of edema and inflammation,” Neuropeptides, vol. 34, no. 5, pp. 314–322, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Starr, R. Graepel, J. Keeble et al., “A reactive oxygen species-mediated component in neurogenic vasodilatation,” Cardiovascular Research, vol. 78, no. 1, pp. 139–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. D. E. Hu, A. S. Easton, and P. A. Fraser, “TRPV1 activation results in disruption of the blood-brain barrier in the rat,” British Journal of Pharmacology, vol. 146, no. 4, pp. 576–584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Erin and O. Ulusoy, “Differentiation of neuronal from non-neuronal Substance P,” Regulatory Peptides, vol. 152, no. 1–3, pp. 108–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. A. Maggi, “The mammalian tachykinin receptors,” General Pharmacology, vol. 26, no. 5, pp. 911–944, 1995. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Hökfelt, C. Broberger, Z. Q. D. Xu, V. Sergeyev, R. Ubink, and M. Diez, “Neuropeptides—an overview,” Neuropharmacology, vol. 39, no. 8, pp. 1337–1356, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. F. T. Lundy and G. J. Linden, “Neuropeptides and neurogenic mechanisms in oral and periodontal inflammation,” Critical Reviews in Oral Biology & Medicine, vol. 15, no. 2, pp. 82–98, 2004. View at Google Scholar
  58. M. Łazarczyk, E. Matyja, and A. Lipkowski, “Substance P and its receptors—as potential target for novel medicines in malignant brain tumour therapies (mini-review),” Folia Neuropathologica, vol. 45, no. 3, pp. 99–107, 2007. View at Google Scholar · View at Scopus
  59. A. Ribeiro-da-Silva and T. Hökfelt, “Neuroanatomical localisation of substance P in the CNS and sensory neurons,” Neuropeptides, vol. 34, no. 5, pp. 256–271, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Cioni, D. Renzi, A. Calabrò, and P. Annunziata, “Enhanced secretion of substance P by cytokine-stimulated rat brain endothelium cultures,” Journal of Neuroimmunology, vol. 84, no. 1, pp. 76–85, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. A. L. Freed, K. L. Audus, and S. M. Lunte, “Investigation of the metabolism of substance P at the blood-brain barrier using capillary electrophoresis with laser-induced fluorescence detection,” Electrophoresis, vol. 22, no. 17, pp. 3778–3784, 2001. View at Google Scholar
  62. R. Matsas, A. J. Kenny, and A. J. Turner, “The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11,” Biochemical Journal, vol. 223, no. 2, pp. 433–440, 1984. View at Google Scholar · View at Scopus
  63. R. A. Skidgel and E. G. Erdos, “The broad substrate specificity of human angiotensin I converting enzyme,” Clinical and Experimental Hypertension A, vol. 9, no. 2-3, pp. 243–259, 1987. View at Google Scholar · View at Scopus
  64. R. A. Skidgel and E. G. Erdös, “Cleavage of peptide bonds by angiotensin I converting enzyme,” Agents and Actions Supplements, vol. 22, pp. 289–296, 1987. View at Google Scholar · View at Scopus
  65. N. M. Hooper and A. J. Turner, “Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism,” Biochemical Journal, vol. 241, no. 3, pp. 625–633, 1987. View at Google Scholar · View at Scopus
  66. T. Sakurada, A. Hara, H. Matsumura, H. Yamada, S. Sakurada, and K. Kisara, “A substance P analogue reduces amino acid contents in the rat spinal cord,” Pharmacology and Toxicology, vol. 66, no. 1, pp. 75–76, 1990. View at Google Scholar · View at Scopus
  67. Y. Wang, V. A. Lance, P. F. Nielsen, and J. M. Conlon, “Neuroendocrine peptides (insulin, pancreatic polypeptide, neuropeptide Y, galanin, somatostatin, substance P, and neuropeptide γ) from the desert tortoise, Gopherus agassizii,” Peptides, vol. 20, no. 6, pp. 713–722, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Kavelaars, D. Broeke, F. Jeurissen et al., “Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL- 6 production,” Journal of Immunology, vol. 153, no. 8, pp. 3691–3699, 1994. View at Google Scholar · View at Scopus
  69. D. Regoli, A. Boudon, and J. L. Fauchére, “Receptors and antagonists for substance P and related peptides,” Pharmacological Reviews, vol. 46, no. 4, pp. 551–599, 1994. View at Google Scholar · View at Scopus
  70. J. C. Hardwick, G. M. Mawe, and R. L. Parsons, “Tachykinin-induced activation of non-specific cation conductance via NK3 neurokinin receptors in guinea-pig intracardiac neurones,” Journal of Physiology, vol. 504, no. 1, pp. 65–74, 1997. View at Publisher · View at Google Scholar · View at Scopus
  71. G. A. Carrasco and L. D. Van De Kar, “Neuroendocrine pharmacology of stress,” European Journal of Pharmacology, vol. 463, no. 1–3, pp. 235–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Kalsner, “The question of feedback at the somadendritic region and antidepressant drug action,” Brain Research Bulletin, vol. 52, no. 6, pp. 467–473, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Lévesque, M. J. Wallman, R. Parent, A. Sík, and A. Parent, “Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra,” Neuroscience Research, vol. 57, no. 3, pp. 362–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Patacchini, C. A. Maggi, and P. Holzer, “Tachykinin autoreceptors in the gut,” Trends in Pharmacological Sciences, vol. 21, no. 5, p. 166, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. T. V. Dam and R. Quirion, “Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain,” Peptides, vol. 7, no. 5, pp. 855–864, 1986. View at Google Scholar · View at Scopus
  76. I. Marriott, “The role of tachykinins in central nervous system inflammatory responses,” Frontiers in Bioscience, vol. 9, pp. 2153–2165, 2004. View at Google Scholar · View at Scopus
  77. A. Saria, “The tachykinin NK1 receptor in the brain: pharmacology and putative functions,” European Journal of Pharmacology, vol. 375, no. 1–3, pp. 51–60, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Okabe, M. Hide, O. Koro, N. Nimi, and S. Yamamoto, “The release of leukotriene B4 from human skin in response to substance P: evidence for the functional heterogeneity of human skin mast cells among individuals,” Clinical and Experimental Immunology, vol. 124, no. 1, pp. 150–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Okabe, M. Hide, O. Koro, and S. Yamamoto, “Substance P induces tumor necrosis factor-α release from human skin via mitogen-activated protein kinase,” European Journal of Pharmacology, vol. 398, no. 2, pp. 309–315, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. M. N. Ghabriel, M. X. Lu, C. Leigh, W. C. Cheung, and G. Allt, “Substance P-induced enhanced permeability of dura mater microvessels is accompanied by pronounced ultrastructural changes, but is not dependent on the density of endothelial cell anionic sites,” Acta Neuropathologica, vol. 97, no. 3, pp. 297–305, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. P. A. Revest, N. J. Abbott, and J. I. Gillespie, “Receptor-mediated changes in intracellular [Ca2+] in cultured rat brain capillary endothelial cells,” Brain Research, vol. 549, no. 1, pp. 159–161, 1991. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Paemeleire, A. De Hemptinne, and L. Leybaert, “Chemically, mechanically, and hyperosmolarity-induced calcium responses of rat cortical capillary endothelial cells in culture,” Experimental Brain Research, vol. 126, no. 4, pp. 473–481, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. T. S. Lu, H. K. Avraham, S. Seng et al., “Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells,” Journal of Immunology, vol. 181, no. 9, pp. 6406–6416, 2008. View at Google Scholar · View at Scopus
  84. P. Annunziata, C. Cioni, R. Santonini, and E. Paccagnini, “Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium,” Journal of Neuroimmunology, vol. 131, no. 1-2, pp. 41–49, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Thornton and R. Vink, “Treatment with a substance p receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease,” PLoS ONE, vol. 7, no. 4, Article ID e34138, 2012. View at Google Scholar
  86. M. S. Kramer, A. Winokur, J. Kelsey et al., “Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression,” Neuropsychopharmacology, vol. 29, no. 2, pp. 385–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. K. M. Lewis, E. Harford-Wright, R. Vink et al., “Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion,” Clinical & Experimental Metastasis, vol. 30, no. 1, pp. 1–12, 2012. View at Google Scholar
  88. C. Palma, M. Bigioni, C. Irrissuto, F. Nardelli, C. A. Maggi, and S. Manzini, “Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft,” British Journal of Cancer, vol. 82, no. 2, pp. 480–487, 2000. View at Google Scholar · View at Scopus
  89. D. J. Goldstein, W. W. Offen, E. G. Klein et al., “Lanepitant, an NK-1 antagonist, in migraine prevention,” Cephalalgia, vol. 21, no. 2, pp. 102–106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Herrstedt, H. B. Muss, D. G. Warr et al., “Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy,” Cancer, vol. 104, no. 7, pp. 1548–1555, 2005. View at Google Scholar
  91. G. Skofitsch and D. M. Jacobowitz, “Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system,” Peptides, vol. 6, no. 4, pp. 721–745, 1985. View at Google Scholar · View at Scopus
  92. P. Geppetti, S. Frilli, D. Renzi et al., “Distribution of calcitonin gene-related peptide-like immunoreactivity in various rat tissues: correlation with substance P and other tachykinins and sensitivity to capsaicin,” Regulatory Peptides, vol. 23, no. 3, pp. 289–298, 1988. View at Google Scholar · View at Scopus
  93. G. Skofitsch and D. M. Jacobowitz, “Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat,” Peptides, vol. 6, no. 4, pp. 747–754, 1985. View at Google Scholar · View at Scopus
  94. J. J. Iliff, L. N. Close, N. R. Selden, and N. J. Alkayed, “A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat,” Experimental Physiology, vol. 92, no. 4, pp. 653–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. I. Márquez-Rodas, F. Longo, R. P. Rothlin, and G. Balfagón, “Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension,” Journal of Physiology and Biochemistry, vol. 62, no. 1, pp. 45–56, 2006. View at Google Scholar · View at Scopus
  96. M. J. Perren, H. E. Connor, and D. T. Beattie, “NK1 and CGRP receptor-mediated dilatation of the carotid arterial bed of the anaesthetized rabbit,” Neuropeptides, vol. 30, no. 2, pp. 141–148, 1996. View at Publisher · View at Google Scholar · View at Scopus
  97. K. J. Escott, H. E. Connor, S. D. Brain et al., “The involvement of calcitonin gene-related peptide (CGRP) and substance P in feline pial artery diameter responses evoked by capsaicin,” Neuropeptides, vol. 29, no. 3, pp. 129–135, 1995. View at Google Scholar
  98. D. W. Busija and J. Chen, “Effects of trigeminal neurotransmitters on piglet pial arterioles,” Journal of Developmental Physiology, vol. 18, no. 2, pp. 67–72, 1993. View at Google Scholar · View at Scopus
  99. D. T. Beattie, C. M. Stubbs, H. E. Connor, and W. Feniuk, “Neurokinin-induced changes in pial artery diameter in the anaesthetized guinea-pig,” British Journal of Pharmacology, vol. 108, no. 1, pp. 146–149, 1993. View at Google Scholar · View at Scopus
  100. M. S. Asghar, A. E. Hansen, T. Kapijimpanga et al., “Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers,” Neurology, vol. 75, no. 17, pp. 1520–1526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. B. Sutter, S. Suzuki, N. F. Kassell, and K. S. Lee, “Characteristics of relaxation induced by calcitonin gene-related peptide in contracted rabbit basilar artery,” Journal of Neurosurgery, vol. 82, no. 1, pp. 91–96, 1995. View at Google Scholar · View at Scopus
  102. M. Alevizaki, A. Shiraishi, and F. V. Rassool, “The calcitonin-like sequence of the β CGRP gene,” The FEBS Letters, vol. 206, no. 1, pp. 47–52, 1986. View at Google Scholar · View at Scopus
  103. S. G. Amara, J. L. Arriza, and S. E. Leff, “Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide,” Science, vol. 229, no. 4718, pp. 1094–1097, 1985. View at Google Scholar · View at Scopus
  104. R. Quirion, D. Van Rossum, Y. Dumont, S. St-Pierre, and A. Fournier, “Characterization of CGRP1 and CGRP2 receptor subtypes,” Annals of the New York Academy of Sciences, vol. 657, pp. 88–105, 1992. View at Google Scholar · View at Scopus
  105. L. M. McLatchie, N. J. Fraser, M. J. Main et al., “RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor,” Nature, vol. 393, no. 6683, pp. 333–339, 1998. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Héroux, M. Hogue, S. Lemieux, and M. Bouvier, “Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1,” Journal of Biological Chemistry, vol. 282, no. 43, pp. 31610–31620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. J. K. Lennerz, V. Rühle, E. P. Ceppa et al., “Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution,” Journal of Comparative Neurology, vol. 507, no. 3, pp. 1277–1299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. M. J. Moreno, J. A. Terrón, D. B. Stanimirovic, H. Doods, and E. Hamel, “Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (RAMPs) in human brain microvascular and astroglial cells in culture,” Neuropharmacology, vol. 42, no. 2, pp. 270–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. M. J. Moreno, Z. Cohen, D. B. Stanimirovic, and E. Hamel, “Functional calcitonin gene-related peptide type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, and cerebromicrovascular or astroglial cells in culture,” Journal of Cerebral Blood Flow and Metabolism, vol. 19, no. 11, pp. 1270–1278, 1999. View at Google Scholar · View at Scopus
  110. J. J. Brokaw and G. W. White, “Calcitonin gene-related peptide potentiates substance P-induced plasma extravasation in the rat trachea,” Lung, vol. 170, no. 2, pp. 85–93, 1992. View at Google Scholar · View at Scopus
  111. P. Le Greves, F. Nyberg, T. Hokfelt, and L. Terenius, “Calcitonin gene-related peptide is metabolized by an endopeptidase hydrolyzing substance P,” Regulatory Peptides, vol. 25, no. 3, pp. 277–286, 1989. View at Google Scholar · View at Scopus
  112. F. Nyberg, P. Le Greves, and L. Terenius, “Modulation of endopeptidase activity by calcitonin gene related peptide: a mechanism affecting substance P action?” Biochimie, vol. 70, no. 1, pp. 65–68, 1988. View at Google Scholar · View at Scopus
  113. S. R. Finfer and J. Cohen, “Severe traumatic brain injury,” Resuscitation, vol. 48, no. 1, pp. 77–90, 2001. View at Publisher · View at Google Scholar · View at Scopus
  114. T. K. McIntosh, D. H. Smith, D. F. Meaney, M. J. Kotapka, T. A. Gennarelli, and D. I. Graham, “Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms,” Laboratory Investigation, vol. 74, no. 2, pp. 315–342, 1996. View at Google Scholar · View at Scopus
  115. B. Jennett, “Epidemiology of head injury,” Archives of Disease in Childhood, vol. 78, no. 5, pp. 403–406, 1998. View at Google Scholar · View at Scopus
  116. R. F. Frankowski, “Descriptive epidemiologic studies of head injury in the United States: 1974–1984,” Advances in Psychosomatic Medicine, vol. 16, pp. 153–172, 1986. View at Google Scholar · View at Scopus
  117. W. T. Chiu, S. J. Huang, S. H. Tsai et al., “The impact of time, legislation, and geography on the epidemiology of traumatic brain injury,” Journal of Clinical Neuroscience, vol. 14, no. 10, pp. 930–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. V. G. Coronado, L. Xu, S. V. Basavaraju et al., “Surveillance for traumatic brain injury-related deaths–United States, 1997–2007,” Morbidity and Mortality Weekly Report, vol. 60, no. -5, pp. 1–36, 2011. View at Google Scholar · View at Scopus
  119. R. Vink and A. J. Nimmo, “Multifunctional drugs for head injury,” Neurotherapeutics, vol. 6, no. 1, pp. 28–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. A. O. Asemota, B. P. George, S. M. Bowman et al., “Causes and trends in traumatic brain injury for United States adolescents,” Journal of Neurotrauma, vol. 30, no. 2, pp. 67–75, 2013. View at Google Scholar
  121. F. P. Rivara, T. D. Koepsell, J. Wang et al., “Incidence of disability among children 12 months after traumatic brain injury,” American Journal of Public Health, vol. 102, no. 11, pp. 2074–2079, 2012. View at Google Scholar
  122. F. P. Rivara, M. S. Vavilala, D. Durbin et al., “Persistence of disability 24 to 36 months after pediatric traumatic brain injury: a cohort study,” Journal of Neurotrauma, vol. 29, no. 15, pp. 2499–2504, 2012. View at Google Scholar
  123. M. Siman-Tov, I. Radomislensky, and K. Pelega, “Reduction in trauma mortality in Israel during the last decade (2000–2010): the impact of changes in the trauma system,” Injury, vol. 2012. View at Publisher · View at Google Scholar
  124. A. Garcia-Altes, K. Perez, A. Novoa et al., “Spinal cord injury and traumatic brain injury: a cost-of-illness study,” Neuroepidemiology, vol. 39, no. 2, pp. 103–108, 2012. View at Google Scholar
  125. M. Majdan, W. Mauritz, A. Brazinova et al., “Severity and outcome of traumatic brain injuries (TBI) with different causes of injury,” Brain Injury, vol. 25, no. 9, pp. 797–805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. G. Petroni, M. Quaglino, S. Lujan et al., “Early Prognosis of severe traumatic brain injury in an urban argentinian trauma center,” Journal of Trauma, vol. 68, no. 3, pp. 564–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. R. Vink and C. van den Heuvel, “Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury,” Neurotherapeutics, vol. 7, no. 1, pp. 74–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Reinert, A. Khaldi, A. Zauner, E. Doppenberg, S. Choi, and R. Bullock, “High extracellular potassium and its correlates after severe head injury: relationship to high intracranial pressure,” Neurosurgical Focus, vol. 8, no. 1, p. e10, 2000. View at Google Scholar · View at Scopus
  129. N. Marklund and L. Hillered, “Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?” British Journal of Pharmacology, vol. 164, no. 4, pp. 1207–1229, 2011. View at Google Scholar
  130. T. Woodcock and M. C. Morganti-Kossmann, “The role of markers of inflammation in traumatic brain injury,” Frontiers in Neurology, vol. 4, p. 18, 2013. View at Google Scholar
  131. A. C. Zacest, R. Vink, J. Manavis, G. T. Sarvestani, and P. C. Blumbergs, “Substance P immunoreactivity increases following human traumatic brain injury,” Acta Neurochirurgica. Supplement, vol. 106, pp. 211–216, 2010. View at Google Scholar · View at Scopus
  132. J. J. Donkin, A. J. Nimmo, I. Cernak, P. C. Blumbergs, and R. Vink, “Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury,” Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 8, pp. 1388–1398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. A. J. Nimmo, I. Cernak, D. L. Heath, X. Hu, C. J. Bennett, and R. Vink, “Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats,” Neuropeptides, vol. 38, no. 1, pp. 40–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Vink, J. J. Donkin, M. I. Cruz, A. J. Nimmo, and I. Cernak, “A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats,” Journal of the American College of Nutrition, vol. 23, no. 5, pp. 538S–540S, 2004. View at Google Scholar · View at Scopus
  135. H. L. Carthew, J. M. Ziebell, and R. Vink, “Substance P-induced changes in cell genesis following diffuse traumatic brain injury,” Neuroscience, vol. 214, pp. 78–83, 2012. View at Google Scholar
  136. E. Harford-Wright, E. Thornton, and R. Vink, “Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury,” Neuroscience Letters, vol. 481, no. 1, pp. 26–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. F. Corrigan, A. Leonard, M. Ghabriel et al., “A substance p antagonist improves outcome in female sprague dawley rats following diffuse traumatic brain injury,” CNS Neuroscience & Therapeutics, vol. 18, no. 6, pp. 513–515, 2012. View at Google Scholar
  138. W. T. Chiu, H. C. Lin, C. Lam, S. F. Chu, Y. H. Chiang, and S. H. Tsai, “Epidemiology of traumatic spinal cord injury: comparisons between developed and developing countries,” Asia-Pacific Journal of Public Health, vol. 22, no. 1, pp. 9–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Wyndaele and J. J. Wyndaele, “Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?” Spinal Cord, vol. 44, no. 9, pp. 523–529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Divanoglou and R. Levi, “Incidence of traumatic spinal cord injury in Thessaloniki, Greece and Stockholm, Sweden: a prospective population-based study,” Spinal Cord, vol. 47, no. 11, pp. 796–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. A. M. Choo, J. Liu, C. K. Lam, M. Dvorak, W. Tetzlaff, and T. R. Oxland, “Contusion, dislocation, and distraction: primary hemorrhage and membrane permeability in distinct mechanisms of spinal cord injury,” Journal of Neurosurgery, vol. 6, no. 3, pp. 255–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Gál, P. Kravčuková, M. Mokrý, and D. Kluchová, “Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review,” Cellular and Molecular Neurobiology, vol. 29, no. 6-7, pp. 1025–1035, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. E. Thornton, J. M. Ziebell, A. V. Leonard, and R. Vink, “Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury,” Molecules, vol. 15, no. 9, pp. 6598–6618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. H. S. Sharma, “Pathophysiology of blood-spinal cord barrier in traumatic injury and repair,” Current Pharmaceutical Design, vol. 11, no. 11, pp. 1353–1389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  145. M. V. D. Berg, J. M. Castellote, I. Mahillo-Fernandez, and J. De Pedro-Cuesta, “Incidence of traumatic spinal cord injury in aragón, Spain (1972–2008),” Journal of Neurotrauma, vol. 28, no. 3, pp. 469–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. J. C. Wu, Y. C. Chen, L. Liu et al., “Effects of age, gender, and socio-economic status on the incidence of spinal cord injury: an assessment using the eleven-year comprehensive nationwide database of Taiwan,” Journal of Neurotrauma, vol. 29, no. 5, pp. 889–897, 2012. View at Google Scholar
  147. A. T. Stammers, J. Liu, and B. K. Kwon, “Expression of inflammatory cytokines following acute spinal cord injury in a rodent model,” Journal of Neuroscience Research, vol. 90, no. 4, pp. 782–790, 2012. View at Google Scholar
  148. K. D. Beck, H. X. Nguyen, M. D. Galvan, D. L. Salazar, T. M. Woodruff, and A. J. Anderson, “Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment,” Brain, vol. 133, no. 2, pp. 433–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. D. S. Tian, J. L. Liu, M. J. Xie et al., “Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats,” Journal of Neurochemistry, vol. 109, no. 6, pp. 1658–1667, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. M. Bilgen, B. Dogan, and P. A. Narayana, “In vivo assessment of blood-spinal cord barrier permeability: serial dynamic contrast enhanced MRI of spinal cord injury,” Magnetic Resonance Imaging, vol. 20, no. 4, pp. 337–341, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. H. Cramer, N. Rosler, K. Rissler, M. C. Gagnieu, and B. Renaud, “Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease,” Neuropeptides, vol. 12, no. 3, pp. 119–124, 1988. View at Google Scholar · View at Scopus
  152. H. S. Sharma, F. Nyberg, Y. Olsson, and P. K. Dey, “Alteration of substance P after trauma to the spinal cord: an experimental study in the rat,” Neuroscience, vol. 38, no. 1, pp. 205–212, 1990. View at Publisher · View at Google Scholar · View at Scopus
  153. N. E. Naftchi, S. J. Abrahams, and H. M. S. Paul, “Localization and changes of substance P in spinal cord of paraplegic cats,” Brain Research, vol. 153, no. 3, pp. 507–513, 1978. View at Publisher · View at Google Scholar · View at Scopus
  154. A. I. Faden, T. P. Jacobs, and C. J. Helke, “Changes in substance P and somatostatin in the spinal cord after traumatic spinal injury in the rat,” Neuropeptides, vol. 6, no. 3, pp. 215–225, 1985. View at Google Scholar · View at Scopus
  155. G. Vita, C. K. Haun, E. F. Hawkins, and W. K. Engel, “Effects of experimental spinal cord transection on substance P receptors: a quantitative autoradiography study,” Neuropeptides, vol. 17, no. 3, pp. 147–153, 1990. View at Publisher · View at Google Scholar · View at Scopus
  156. L. N. Novikova, M. Brohlin, P. J. Kingham et al., “Neuroprotective and growth-promoting effects of bone marrow stromal cells after cervical spinal cord injury in adult rats,” Cytotherapy, vol. 13, no. 7, pp. 873–887, 2011. View at Google Scholar
  157. M. D. Christensen and C. E. Hulsebosch, “Spinal cord injury and anti-NGF treatment results in changes in CGRP density and distribution in the dorsal horn in the rat,” Experimental Neurology, vol. 147, no. 2, pp. 463–475, 1997. View at Publisher · View at Google Scholar · View at Scopus
  158. C. J. Murray, T. Vos, R. Lozano et al., “Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2197–2223, 2013. View at Google Scholar
  159. J. Mackay and G. Mensah, The Atlas of Heart Disease and Stroke, World Health Organization, Geneva, Switzerland, 2004.
  160. J. B. Zhang, Z. Y. Ding, Y. Yang et al., “Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation,” Neurological Research, vol. 32, no. 4, pp. 353–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. P. Lipton, “Ischemic cell death in brain neurons,” Physiological Reviews, vol. 79, no. 4, pp. 1431–1568, 1999. View at Google Scholar · View at Scopus
  162. R. R. Leker and E. Shohami, “Cerebral ischemia and trauma—different etiologies yet similar mechanisms: neuroprotective opportunities,” Brain Research Reviews, vol. 39, no. 1, pp. 55–73, 2002. View at Publisher · View at Google Scholar · View at Scopus
  163. Y. Xian, R. G. Holloway, W. Pan et al., “Challenges in assessing hospital-level stroke mortality as a quality measure: comparison of ischemic, intracerebral hemorrhage, and total stroke mortality rates,” Stroke, vol. 43, no. 6, pp. 1687–1690, 2012. View at Google Scholar
  164. A. E. Doyle, “A review of the short-term benefits of antihypertensive treatment with emphasis on stroke,” American Journal of Hypertension, vol. 6, no. 3, pp. 6S–8S, 1993. View at Google Scholar · View at Scopus
  165. M. Venti, “Subarachnoid and intraventricular hemorrhage,” Frontiers in Human Neuroscience, vol. 30, pp. 149–153, 2012. View at Google Scholar
  166. H. Memezawa, M. L. Smith, and B. K. Siesjo, “Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats,” Stroke, vol. 23, no. 4, pp. 552–559, 1992. View at Google Scholar · View at Scopus
  167. E. H. Lo, A. B. Singhal, V. P. Torchilin, and N. J. Abbott, “Drug delivery to damaged brain,” Brain Research Reviews, vol. 38, no. 1-2, pp. 140–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. G. Corso, E. Bottacchi, G. Giardini et al., “Epidemiology of stroke in Northern Italy: the Cerebrovascular Aosta Registry, 2004–2008,” Neurological Sciences, 2012. View at Publisher · View at Google Scholar
  169. T. Kuroiwa, N. Miyasaka, Z. Fengyo et al., “Experimental ischemic brain edema: morphological and magnetic resonance imaging findings,” Neurosurgical Focus, vol. 22, no. 5, p. E11, 2007. View at Google Scholar · View at Scopus
  170. G. A. Rosenberg, “Ischemic brain edema,” Progress in Cardiovascular Diseases, vol. 42, no. 3, pp. 209–216, 1999. View at Publisher · View at Google Scholar · View at Scopus
  171. Z. Yu, G. Cheng, X. Huang, K. Li, and X. Cao, “Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia,” NeuroReport, vol. 8, no. 9-10, pp. 2117–2119, 1997. View at Google Scholar · View at Scopus
  172. R. J. Turner, P. C. Blumbergs, N. R. Sims, S. C. Helps, K. M. Rodgers, and R. Vink, “Increased substance P immunoreactivity and edema formation following reversible ischemic stroke,” Acta Neurochirurgica, Supplementum, no. 96, pp. 263–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  173. R. Turner and R. Vink, “Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke,” Timely Topics in Medicine. Cardiovascular Diseases, vol. 11, p. E24, 2007. View at Google Scholar · View at Scopus
  174. R. J. Turner, S. C. Helps, E. Thornton, and R. Vink, “A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke,” Brain Research, vol. 1393, pp. 84–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. R. J. Turner and R. Vink, “Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats,” Neuroscience, vol. 220, pp. 1–10, 2012. View at Google Scholar
  176. E. Preston, G. Sutherland, and A. Finsten, “Three openings of the blood-brain barrier produced by forebrain ischemia in the rat,” Neuroscience Letters, vol. 149, no. 1, pp. 75–78, 1993. View at Publisher · View at Google Scholar · View at Scopus
  177. G. Bruno, F. Tega, A. Bruno et al., “The role of substance P in the cerebral ischemia,” International Journal of Immunopathology and Pharmacology, vol. 16, no. 1, pp. 67–72, 2003. View at Google Scholar · View at Scopus
  178. D. K. Kim, E. K. Oh, B. A. Summers, N. R. Prabhakar, and G. K. Kumar, “Release of substance P by low oxygen in the rabbit carotid body: evidence for the involvement of calcium channels,” Brain Research, vol. 892, no. 2, pp. 359–369, 2001. View at Publisher · View at Google Scholar · View at Scopus
  179. N. H. Khatibi, V. Jadhav, S. Charles et al., “Capsaicin pre-treatment provides neurovascular protection against neonatal hypoxic-ischemic brain injury in rats,” Acta Neurochirurgica, Supplementum, no. 111, pp. 225–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  180. C. M. Barry, S. C. Helps, C. V. Den Heuvel, and R. Vink, “Characterizing the role of the neuropeptide substance P in experimental subarachnoid hemorrhage,” Brain Research, vol. 1389, pp. 143–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  181. Z. Liu, Q. Liu, H. Cai et al., “Calcitonin gene-related peptide prevents blood-brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion,” Regulatory Peptides, vol. 171, no. 1–3, pp. 19–25, 2011. View at Google Scholar
  182. G. Liu, H. Cai, X. Xu et al., “The effects of calcitonin gene-related peptide on bFGF and AQP4 expression after focal cerebral ischemia reperfusion in rats,” Pharmazie, vol. 65, no. 4, pp. 274–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. J. Y. Zhang, G. T. Yan, J. Liao et al., “Leptin attenuates cerebral ischemia/reperfusion injury partially by CGRP expression,” European Journal of Pharmacology, vol. 671, no. 1—3, pp. 61–69, 2011. View at Google Scholar
  184. R. Juul, H. Hara, S. E. Gisvold et al., “Alterations in perivascular dilatory neuropeptides (CGRP, SP, VIP) in the external jugular vein and in the cerebrospinal fluid following subarachnoid haemorrhage in man,” Acta Neurochirurgica, vol. 132, no. 1–3, pp. 32–41, 1995. View at Publisher · View at Google Scholar · View at Scopus
  185. L. Edvinsson, R. Juul, and I. Jansen, “Perivascular neuropeptides (NPY, VIP, CGRP and SP) in human brain vessels after subarachnoid haemorrhage,” Acta Neurologica Scandinavica, vol. 90, no. 5, pp. 324–330, 1994. View at Google Scholar · View at Scopus
  186. R. Juul, S. Aakhus, K. Björnstad, S. E. Gisvold, A. O. Brubakk, and L. Edvinsson, “Calcitonin gene-related peptide (human α-CGRP) counteracts vasoconstriction in human subarachnoid haemorrhage,” Neuroscience Letters, vol. 170, no. 1, pp. 67–70, 1994. View at Publisher · View at Google Scholar · View at Scopus
  187. D. Rosselli and J. D. Rueda, “Burden of pneumococcal infection in adults in Colombia,” Journal of Infection and Public Health, vol. 5, no. 5, pp. 354–359, 2012. View at Google Scholar
  188. S. H. Shin and K. S. Kim, “Treatment of bacterial meningitis: an update,” Expert Opinion on Pharmacotherapy, vol. 13, no. 15, pp. 2189–2206, 2012. View at Google Scholar
  189. V. S. Chauhan, D. G. Sterka, D. L. Gray, K. L. Bost, and I. Marriott, “Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi,” Journal of Immunology, vol. 180, no. 12, pp. 8241–8249, 2008. View at Google Scholar · View at Scopus
  190. A. Rasley, I. Marriott, C. R. Halberstadt, K. L. Bost, and J. Anguita, “Substance P augments Borrelia burgdorferi-induced prostaglandin E2 production by murine microglia,” Journal of Immunology, vol. 172, no. 9, pp. 5707–5713, 2004. View at Google Scholar · View at Scopus
  191. V. S. Chauhan, J. M. Kluttz, K. L. Bost, and I. Marriott, “Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis,” Journal of Immunology, vol. 186, no. 12, pp. 7255–7263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  192. R. M. G. Berg, G. I. Strauss, F. Tofteng et al., “Circulating levels of vasoactive peptides in patients with acute bacterial meningitis,” Intensive Care Medicine, vol. 35, no. 9, pp. 1604–1608, 2009. View at Publisher · View at Google Scholar · View at Scopus